Biocon Biologics
Neeraj Narayanan has a strong background in bioprocess technology, with experience working in various roles in the biopharmaceutical industry. Currently serving as a Scientific Manager at Biocon Biologics, Neeraj is responsible for process development of biosimilar monoclonal antibodies. In previous roles, including as a Principal Scientist and Associate Scientific Manager, Neeraj has demonstrated expertise in downstream process development and scale-up of novel fusion monoclonal antibodies. With a M.Tech in Bio-Process Technology from the Institute of Chemical Technology, Neeraj has a solid foundation for their work in the industry.
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics